Hepatology
Conference Coverage
HBV: Rethink the free pass for immune tolerant patients
MAUI, HAWAII – Not treating means more liver cancer.
Conference Coverage
NASH ‘an epidemic of the 21st century’
LOS ANGELES – Recent guidelines recognize the association between diabetes, NAFLD, and NASH, and call for more vigilance and screening tests.
Conference Coverage
Novel approaches to treating NASH in diabetes
BARCELONA –
Conference Coverage
What’s new in hepatitis C: Four themes that dominated at the Liver Meeting
BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy,...
News
AASLD debrief: Five drugs show promise in NAFLD (and two do not)
BOSTON – Promising new data for cotadutide, licogliflozin, tropifexor, saroglitazar, and PF-05221304 highlighted in...
Conference Coverage
TARGET-NASH: One-third of NAFLD, NASH patients lost weight, but not all kept it off
BOSTON – With no approved pharmacologic treatments for NAFLD and NASH, weight reduction remains one of the mainstays of treatment.
News
Direct-acting antiviral therapy boosts survival for infected HCC patients
Adults with a history of hepatocellular carcinoma had a significantly reduced risk of death after treatment of HCV infections with DAAs.
News
Patients with viral hepatitis are living longer, increasing risk of extrahepatic mortality
In sharp contrast with the viral hepatitis findings, mortality rates among patients with ALD and NAFLD have increased.
News
Some HCV medications associated with serious liver injury
In many cases, the medications should never have been prescribed, according to the FDA.
News
USPSTF issues draft recommendation statement for HCV screening in adults
The proposal represents an update and expansion of USPSTF’s current recommendation.